Advertisement
Screener

SERA PROGNOSTICS, INC. (SERA) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

1.6 / 5 stars · 17/54 Roast Me

SERA PROGNOSTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

SERA PROGNOSTICS, INC. (SERA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.13 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-18

  • SERA PROGNOSTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.13, a 61.55% decline from fiscal 2024.
  • SERA PROGNOSTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.54, a 142.98% increase from fiscal 2023.
  • SERA PROGNOSTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.28, a 18.75% increase from fiscal 2022.
  • SERA PROGNOSTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.92, a 65.96% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month
2025-12-31$2.13
10-K · filed 2026-03-18
2024-12-31$5.54
10-K · filed 2026-03-18
2023-12-31$2.28
10-K · filed 2025-03-19
2022-12-31$1.92
10-K · filed 2024-03-20
2021-12-31$5.64
10-K · filed 2023-03-22
2021-06-30$5.54
10-Q · filed 2021-08-30
2020-12-31$0.93
10-K · filed 2022-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45